IlluminaILMN
ILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 8,970
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
70% more call options, than puts
Call options by funds: $337M | Put options by funds: $199M
65% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 83
11% more capital invested
Capital invested by funds: $18.4B [Q3] → $20.6B (+$2.11B) [Q4]
8.3% more ownership
Funds ownership: 88.74% [Q3] → 97.04% (+8.3%) [Q4]
7% more funds holding in top 10
Funds holding in top 10: 14 [Q3] → 15 (+1) [Q4]
3% more funds holding
Funds holding: 790 [Q3] → 814 (+24) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 249 | Existing positions reduced: 297
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$100
6%
upside
Avg. target
$160
70%
upside
High target
$247
162%
upside
7 analyst ratings
3 positive
43%
3 neutral
43%
1 negative
14%
Morgan Stanley Tejas Savant 22% 1-year accuracy 4 / 18 met price target | 44%upside $136 | Equal-Weight Maintained | 11 Feb 2025 |
Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target | 102%upside $190 | Overweight Maintained | 10 Feb 2025 |
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target | 6%upside $100 | Underweight Downgraded | 10 Feb 2025 |
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target | 162%upside $247 | Outperform Maintained | 7 Feb 2025 |
Canaccord Genuity Kyle Mikson 46% 1-year accuracy 13 / 28 met price target | 43%upside $135 | Hold Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 32 articles about ILMN published over the past 30 days
Neutral
PRNewsWire
22 hours ago
Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three years SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years.
Neutral
PRNewsWire
2 days ago
Illumina unveils first-of-its-kind spatial transcriptomics technology
Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands software portfolio to decode multimodal data with Illumina Connected Multiomics SAN DIEGO , Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.
Neutral
PRNewsWire
3 days ago
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference. The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).
Neutral
Zacks Investment Research
3 days ago
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Negative
Barrons
1 week ago
Trump's Cuts to Medical Research Are Hurting These Stocks
Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.
Positive
Zacks Investment Research
1 week ago
Here's Why Illumina (ILMN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
Zacks Investment Research
1 week ago
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Positive
Zacks Investment Research
1 week ago
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Negative
The Motley Fool
1 week ago
Why Illumina Stock Got Mashed on Monday
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.
Negative
Zacks Investment Research
1 week ago
Illumina (ILMN) International Revenue Performance Explored
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Charts implemented using Lightweight Charts™